Precigen’s Financial Crossroads: Can New Funding and FDA Approval Steer a Turnaround?

While Precigen recently secured a $125 million credit facility and gained full FDA approval for its flagship product, AdenoVerse PRZIME (previously referred to as PAPZIMEOS), its latest quarterly earnings reveal a company in a precarious financial position. The stark contrast between these developments paints a complex picture for the biotechnology firm.

The company’s second-quarter 2025 financial statements delivered sobering news. Precigen reported a net loss of $80.8 million for the first six months of the year. Operational activities consumed $35.3 million in cash. Prior to the... Read more...